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 Preface 
 
This editorial by Franklin, Ospina Betancurt and Camporesi addresses the 2017/18 
debate on the role of testosterone in athletic performance. The authors outline what 
they contend are statistical flaws in the evidence filed by IAAF to the Court of 
Arbitration for Sport in the discussion about the role of hyperandrogenism in women 
and improved performance in track & field. The reader is directed to the relevant 
context in the boxed item for the background of this discussion, and to the companion 
piece in BJSM by Camporesi 2018 for a discussion of the ethical issues of the same 
case. 
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CONTENT FOR BOXED ITEM 
 
Background on Dutee Chand vs AFI & IAAF case 
IAAF Hyperandrogenism Regulations were in place from May 1, 2011 to July 27, 
2015, when they were suspended by the Court of Arbitration for Sport (CAS). The 
regulations stated that female athletes who naturally produce levels of testosterone 
higher than 10 nmol/lit were not eligible to compete in the female category and need 
to take androgen suppressive drugs to resume competition. Dutee Chand, an Indian 
sprinter, was asked to abide by these Regulations in July 2014 and appealed to CAS 
on grounds that the Regulations unfairly discriminated against women who naturally 
produced higher levels of testosterone. CAS was not satisfied with the evidence IAAF 
provided and hence suspended the Regulations on July 27, 2015,
3
 but allowed IAAF 
up to two years (later extended by two months) to submit additional evidence on the 
correlation between endogenous levels of testosterone and athletic performance. The 
Regulations currently remain suspended until July 19, 2018. 
 
Word-count: 799 (w/o boxed item); 962 (including boxed item) 
 
How can performance data resolve the arbitration of sensitive matters in the world of 
sports? In the absence of experimental data (i.e. clinical trials), researchers must build 
an argument based on correlations in observational data. Such data are often not 
widely available. The case in Dutee Chand vs AFI & IAAF is a case in point. [see 
boxed item] 
Bermon and Garnier (2017)1 use correlations between free testosterone (fT) 
and athletic performance across 21 women’s events to claim that women with high fT 
have a performance advantage in a very specific subset of athletic events. On 29 
September 2017, their data were filed as evidence by IAAF to CAS in the Dutee 
Chand vs AFI & IAAF case. These data added to draft revised regulations [not 
available in the public domain] that would apply only to female track events over 
distances of between 400 metres and one mile.   
The CAS Panel has made no ruling (as of January 28, 2018) about the 
sufficiency of the evidence put forward by IAAF. As of a press release dated January 
19, 2018, the regulations remain suspended for an additional six months at which time 
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the IAAF was to advise CAS on how it intends to implement the regulations moving 
forward. 2  
We argue that the evidence put forward by Bermon and Garnier(1) is not 
sufficient to sustain even draft revised regulations applying only to specific events. 
We have reanalysed the available data presented by Bermon and Garnier(1) that 
suggests, at the very least, that further analysis is required to establish the claims 
made in the paper. 
The application of statistical techniques, and interpretation of results, in such 
studies are not neutral, nor standardized; correlations in observational data require 
careful interpretation by independent researchers with access to the original data. Can 
the data used in Bermon and Garnier (1) tell us something about whether testosterone 
confers an advantage in particular events, individually, or just whether there is an 
overall correlation across all events?  
We argue that, given the sample sizes used for each event, and the number of 
statistical tests conducted by the authors, any particular significant result in an event 
is more likely to arise by chance. Unfortunately, without publically available raw 
data, it is not possible to perform all the desired robustness checks on the data. In lieu 
of access to such data we performed a Fisher’s combination test using the p-values 
calculated from the published data. After performing such test we were unable to 
reject the global null hypothesis that all null hypotheses are true, i.e. the pattern of p-
values is not inconsistent with there being no advantage to high fT women, in any one 
of the events. In simpler terms: it is possible that the correlations presented in the 
paper (even the largest ones) occurred simply by chance.  
Given the number of tests performed, the few significant findings detected 
could have arisen without there being a true correlation between testosterone and 
performance for female athletes. To avoid these chance findings (also known as ‘false 
positives’) appropriate multiple hypothesis testing corrections ought to be applied.  
Our re-analysis of the data [see supplementary web-content for additional 
details] suggests that either of these approaches seems unlikely to yield a robust and 
significant correlation. Given these findings, we believe that it is scientifically 
incorrect to draw the conclusions in the Bermon and Garnier(1) paper from the 
statistical results presented. Their paper claims that certain athletes have an advantage 
in precisely the five events where a significant effect was found: we calculate that a 
high share of those five significant effects are likely to be false positives. The overall 
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range of coefficients across all events is large: the average advantage to high 
testosterone women is estimated to be 0.7%, with a minimum of -2.6% and a 
maximum of 4.5% across the 21 events, and only in 12 (57%) of the events do higher 
fT athlete perform better on average. With access to the data, a more sensible test 
might be one single test of correlation conducted across all events.   
 In light of our re-analysis, we conclude that:  
1. Raw data used in such studies, that will have direct implications for real world 
outcomes, should be made publically available for other researchers to 
analyse.  
2. Interpretation of estimated correlations should also be conducted with great 
caution, and be referred to independent statisticians. While we do not claim to 
play the role of such an independent statistical arbitrator in this case 
(especially since we have not had access to the raw data), our statistical 
analysis already allows one to conclude that the article by Bermon and Garnier 
(1) does not meet the standard of proof set by the CAS, without further 
analysis. Independent analysis is necessary in this situation, and others like it.  
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SUPPLEMENTARY MATERIAL FOR WEB CONTENT  
 
1. WHAT CAN WE ACTUALLY CONCLUDE FROM THE RESULTS IN 
BERMON AND GARNIER 2017?  
 
 
  
1.1  Robustness and replicability 
Statistical analyses of observational data are subject to numerous choices, also 
known as ‘researchers’ degrees of freedom’: researchers must choose which test to 
apply, how to define outcome variables, how to divide up the data, and which 
statistical threshold to use. In Bermon and Garnier (2017) 1 the authors use a single 
test, applied to each event. The authors divide the sample into tertiles by testosterone 
levels (three equally sized groups with low-, intermediate- and high- levels of free 
testosterone (fT), respectively) and compare the average performance in the high 
group to those average performance in the low group.  
 This particular choice of statistical analysis is not conventional, and is one of 
many ways that it could have been done. We would like to see numerous additional 
robustness tests, especially since, to the best of our knowledge, this tertile comparison 
test is not standard in this literature. A more natural test would be to report the raw 
correlation between fT levels and performance in the sample as a whole.  
 In addition, we are left to wonder if the results in Bermon and Garnier (2017) 
tell us anything about the performance of extreme outliers in terms of fT (ie. athletes 
near the 10nmol/L threshold previously imposed by the IAAF) relative to the average 
athlete. After all, the results only tell us something about the performance of the 
highest tertile relative to the lowest tertile. The authors are unable to say anything 
conclusive about the effect of having testosterone levels above the 10 nmol/L 
threshold, since they are likely to have small samples at this level. This is surely a 
point worth mentioning, as the relevant question in the CAS hearings relates to 
athletes above the 10 nmol/L threshold.  
 
1.2  Multiple hypothesis testing and interpretation.  
Can the data used in Bermon and Garnier 2017 tell us something about whether 
testosterone confers an advantage in particular events, individually, or just whether 
there is an overall correlation across all events? We argue that, given the sample sizes 
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used for each event, and the number of statistical tests conducted by the authors, any 
particular significant result in an event is more likely to arise by chance. Given the 
number of tests performed, the few significant findings detected could have arisen 
without there being a true correlation between testosterone and performance for 
female athletes. To avoid these chance findings (also known as ‘false positives’) 
appropriate multiple hypothesis testing corrections ought to be applied. Alternatively, 
a single test of correlation across all events should be conducted. Our analysis of the 
data suggests that either of these approaches seems unlikely to yield a robust and 
significant correlation.  
 
 First, we note that two different types of hypotheses could be tested with the 
data used in Bermon and Garnier 2017, as one could test a) for an effect of fT on 
performance in each event separately, and draw separate conclusions specific to each 
event (as is done in this paper); or b)  one could test for an effect of fT on 
performance in athletics events, in general. We address these two types of arguments 
in turn:  
 
a) Independent tests across multiple events: 
Because there are many hypotheses tested in Bermon and Garnier 2017, we are 
concerned that one or more of their five reported successes (five events) are likely to 
be false positives, i.e. that the null hypothesis has been rejected when in fact it is true 
(in other words, the authors conclude that there is a relationship, when in fact there is 
none and they are detecting only noise in the data). If one significant test is performed 
and found to be significant, there is <0.05 chance that the null hypothesis should not 
have been rejected. But as the number of tests increases, the probability that at least 
one of the rejected null hypotheses should not have been rejected starts to increase. 
For instance, if the true effect of fT on performance was zero across all events, and 
tests are conducted for 43 events (men and women), we’d expect two to be significant 
by chance, on average. If we just looked among the 21 women’s events, we’d expect 
one to be true by chance, on average. So it seems likely that at least one of the 
significant results reported in the paper is a false positive. For instance, when the 
authors claim that there is an advantage in the hammer throw, we cannot be sure that 
this is a robust finding. This is a well-studied problem in statistical sciences, for 
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which there are many proposed solutions.2 Note that this problem arises regardless of 
whether the tests are independent or not.  
We have hence applied a correction procedure which controls the false discovery 
rate across the tests conducted in the paper: that is, the overall proportion of reported 
significant findings that are likely to be false positives. We apply the procedure 
suggested by Benjamini et al. (2006)2 to the p-values calculated in the first part of this 
section. If we apply this correction we find that the lowest corrected p-value (for the 
event with the largest difference) is 0.239.
1
 This means that, given the number of tests 
performed, there is at least a 24% chance that we could have found such a large 
correlation simply by chance. This correction is far less harsh than other corrections 
that control the family-wise error-rate, such as the very conservative Bonferroni 
correction,3 which uses a stricter threshold of statistical significances (that means that, 
if we apply the Bonferroni correction, we are going to find a higher chance that the 
results in Bermon and Garnier 2017 have arisen simply by chance). Given these 
findings, we believe that it is scientifically incorrect to draw the conclusions about the 
specific five events claimed in the paper, as we are unable to state with any 
confidence that each result is not a false-positive.  
 
b)  Testing for an advantage across all events 
Given multiple hypothesis testing problems, the dataset used in Bermon and 
Garnier 2017 is not large enough to conclusively identify those events that exhibit a 
correlation, and those that do not. Might one argue, instead, that there is evidence for 
an average effect of fT on performance, across all events? After all, the regulations 
covering testosterone among female athletes would likely apply to all athletes, not just 
the events highlighted in the conclusion of this paper. Having established whether 
there is a significant treatment effect on average, a researcher might then test whether 
there is evidence for heterogeneity in the effect size across different events.  
 Unfortunately, without publically available raw data, it is not possible to 
perform all of the desired robustness checks on the data. Ideally, researchers with 
access to the raw data should calculate standardized performance scores for each 
observation, pool those data across all events, and look for an average effect across 
                                                        
1 There are some cases where the tables in the original paper leave some ambiguity about the 
underlying data structure (not least, some ambiguity about the total sample size in each tertile). 
In all such cases we have made assumptions that would bias us in favour of lower p-values, so if 
anything, the corrections we have applied are conservative. 
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the full sample. In lieu of access to such data we performed a Fisher’s combination 
test using the p-values calculated from the published data. After performing such test 
we are unable to reject the “global” null hypothesis that all null hypotheses are true, 
i.e. the pattern of p-values found in the paper, across all women’s events, is not 
inconsistent with there being no advantage to high fT women, in any of the events. In 
simpler terms: it is possible that the correlations presented in the paper occurred 
simply by chance. Therefore, researchers and practitioners should interpret the 
statistical results in Bermon and Garnier 2017 with extreme caution.   
 
 
2. DO THE BEST ESTIMATES OF THE ADVANTAGE TO HIGH 
TESTOSTERONE WOMEN MEET THE THRESHOLD SET BY CAS? 
 
In CAS Interim Award of July 2015,4 the Panel accepted the evidence that male 
athletes have a competitive advantage over female athletes on the order of 10-12 %. 
As further evidence for the re-opening of the Dutee Chand vs AFI & IAAF case, we 
would like to point to some original data collected by Ospina Betancurt
5,6
 as part of a 
doctoral thesis, now partially published. The objective of this doctoral study was to 
investigate the difference in athletic performance between women with and without 
hyperandrogenism competing at an elite level in track and field, in order to establish 
whether sportswomen with hyperandrogenism obtained a performance of 10-12 % 
and hence whether there is a justification in the regulation of the eligibility of female 
athletes with hyperandrogenism as required by CAS. The study, recently published 
for the Journal of Sport Sciences
4
, confirms that the threshold set by CAS, with 
respect to the difference between male and female athletes, is indeed correct. 
The CAS Panel also noted that the assumption underlying the Hyperandrogenism 
Regulations is that “endogenous testosterone level within the male range + virilisation 
(indicating sensitivity to the high levels of testosterone) = a degree of competitive 
advantage over non-hyperandrogenic females of commensurate significance to the 
competitive advantage that male athletes enjoy over female athletes” [emphasis 
added].
 4 p.154
 The Panel was not satisfied that this assumption was proven valid, hence 
the suspension of the Regulations. It is important to note that once the requested 
further evidence was put forward establishing a certain degree of advantage of 
hyperandrogenic athletes over non-hyperandrogenic athletes, the Panel would have to 
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consider “if the degree of advantage were well below 12 %, whether that justified 
excluding women with that advantage from the female category”. 4 p.155 As 
demonstrated by our reanalysis, we have serious reasons to question whether the true 
effect in Bermon and Garnier 2017 falls in the reported range of 1.8-4.5 %. 
 
 
3. CONCLUSIONS 
 
The finding of a significant difference in performance in a small subset of 
statistical tests does not mean a correlation exists for each of them. We have argued 
that Bermon and Garnier 2017’s analysis is vulnerable to problems of false positives, 
and requires the application of multiple hypothesis test corrections. In other words, 
the statistical tables presented in a paper such as Bermon and Garnier 2017 cannot 
“speak for themselves”: both the selection of statistical tests and the interpretation of 
particular statistical differences require important statistical robustness checks. 
Further, we noted how the authors’ choice to make claims about specific events 
(i.e. that high testosterone confers an advantage in five specific events alone and, 
presumably, not the other events) is not obvious, and likely to be inappropriate, since 
it is understood that their paper is likely to influence the policy discussion about 
whether testosterone levels should be regulated across all female events. In our paper 
we have argued that the sample size, and effect sizes, in Bermon and Garnier 2017, 
are simply not large enough to make robust claims about each event separately.  
A more reasonable, and policy-appropriate, use of the data would be to establish 
an average correlation between fT and performance across events.  However, our 
reanalysis of the results in Bermon and Garnier 2017 suggest that there is no evidence 
for such an overall correlation, and allows us to conclude that it is not only inaccurate 
for the authors to state that there is an advantage of between 1.8% to 4.5% for high fT 
female athletes in general, it is in fact inaccurate to conclude that is the size of 
advantage in these specific 5 events. After correcting for multiple hypothesis testing, 
no differences would be individually significant. And, across all events, the average 
advantage to high testosterone women is estimated to be 0.7%, with a minimum of -
2.6% and a maximum of 4.5% across the 21 events, and only in 12 (57%) of the 
events do higher fT athlete perform better on average.  
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In light of our re-analysis, we conclude first that raw data used in such studies, 
that will have direct implications for real world outcomes, should be made publically 
available for other researchers to analyse. In a field where such data is often propriety 
and difficult for independent researchers to access, efforts should be made to 
anonymize such data and make it publicly available. Second, we conclude that the 
interpretation of estimated correlations should also be conducted with great caution, 
and be referred to independent statisticians.  
While do not claim to play the role of such an independent statistical arbitrator in 
this case (especially since we have not had access to the raw data), our statistical 
analysis already allows one to conclude that the article by Bermon and Garnier 2017 
does not meet the standard of proof set by the CAS, without further analysis, and 
provides the argument that this independent analysis is necessary in this situation, and 
others like it.  
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